Although most inhibitors are still in the preclinical phase, the targeting of glycolytic enzymes, such as PKM2 and LDHA, represents a very promising therapeutic approach for the treatment of pancreatic cancer. The gene discussed is PKM; the disease is familial pancreatic carcinoma.